HCA Healthcare, Inc.

(New York Stock Exchange)
Back to all articles
Slightly Bullish +20

HCA Healthcare (HCA) Stock Forecast & Price Target (2026)

Earnings report AI-generated analysis

📈 HCA Healthcare trades at $451.09 with a consensus analyst target of $450.00 and a CleaRank fair value of $450.00, resulting in a 'Hold' rating.

💰 The company beat Q2 2026 EPS estimates by 1.2%, leading to a 1.94% stock price increase that indicates positive earnings momentum.

📉 Insiders have sold a net $38.5 million in HCA Healthcare stock, signaling potential lack of confidence in the short-term outlook.

💵 HCA's P/E ratio is significantly lower than the sector median, suggesting the stock may be undervalued despite poor profitability metrics.

📊 Technical analysis shows the stock trading above its 50-day and 200-day moving averages with a bullish RSI of 64.9.

🔮 Monte Carlo simulations project a base-case price near $727 for HCA by 2030, representing a 1.6x return over four years from current levels.

📉 Historical backtesting shows a $10,000 investment in HCA since October 2016 would be worth about $59,542 today compared to $36,479 for the S&P 500.

Bullish Signals
  • HCA Healthcare beat Q2 2026 EPS estimates by 1.2%, driving a 1.94% stock price increase that indicates positive earnings momentum.
  • The stock is trading above its key moving averages (50-day SMA, 200-day SMA) with a bullish RSI of 64.9, indicating positive technical trends.
  • HCA's P/E ratio is significantly lower than the sector median, suggesting the stock may be undervalued relative to peers.
Risk Factors
  • Insiders have sold a net $38.5 million in HCA Healthcare stock, signaling a potential lack of confidence in the short-term outlook.
  • Despite a lower P/E ratio, the company is facing poor profitability metrics which temper the undervaluation thesis.
Full Analysis
HCA Healthcare (HCA) is currently trading at $451.09 as of October 11, 2026, with analyst consensus and CleaRank Financial AI fair value estimates both set at $450.00, resulting in a 'Hold' rating. Technical indicators show the stock trading above its 50-day average of $420.71 with an RSI of 65, suggesting neutral-to-bullish momentum relative to key moving averages. HCA Healthcare reported a beat on Q2 2026 earnings per share (EPS), exceeding estimates by 1.2% and driving a 1.94% increase in the stock price, which signals positive short-term earnings momentum. However, this optimism is tempered by insider activity, as insiders have netted a $38.5 million sale of HCA stock, potentially indicating a lack of confidence in the immediate future outlook. Valuation metrics present a mixed picture for investors, with HCA's P/E ratio significantly lower than the sector median, suggesting potential undervaluation despite poor profitability metrics. Long-term simulations project a base-case price near $727 by 2030, representing a 1.6x return over four years, though these are statistical outcomes based on historical volatility rather than guaranteed targets. The article concludes with standard disclaimers noting that the analysis is for educational purposes only and does not constitute financial advice. Historical backtests indicate that a $10,000 investment in HCA since 2016 would have grown to approximately $59,542, significantly outperforming the S&P 500 benchmark over the same period.